Pharmacokinetics of carboplatin and etoposide in a haemodialysis patient with Merkel-cell carcinoma.
We present a Merkel-cell carcinoma patient with chronic renal failure requiring haemodialysis and evaluate the pharmacokinetics of carboplatin and etoposide during haemodialysis. The area under the concentration-time curve of carboplatin was increased by prolonging the interval between administration and haemodialysis. However, that of etoposide was not changed. Carboplatin showed good membrane permeability in haemodialysis, while etoposide showed no permeability. In conclusion, the pharmacokinetics of carboplatin could be controlled by haemodialysis and the interval between chemotherapy and haemodialysis. However, the pharmacokinetics of etoposide were not affected.
Suzuki
S
S
Department of Internal Medicine, Hyogo Prefectural Awaji Hospital, Japan.
Koide
M
M
Sakamoto
S
S
Matsuo
T
T
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D016190:Carboplatin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D015266:Carcinoma, Merkel Cell / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D005047:Etoposide / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000378:metabolism / Q000628:therapy; D006435:Renal Dialysis; D013997:Time Factors
D005047:Etoposide; D016190:Carboplatin